Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society 68th Annual Scientific Meeting
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2026 Annual Meeting
Axsome Therapeutics Announces FDA Approval of AUVELITY® for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
BTV Spotlights: NevGold, Calian Group, Talisker Resources, Dakota Gold, Oreterra Metals, Titan Mining, Nevada Organic Phosphate, Osisko Development
BTV Spotlights: NevGold, Calian Group, Talisker Resources, Dakota Gold, Oreterra Metals, Titan Mining, Nevada Organic Phosphate, Osisko Development
SAGA Metals Completes Acquisition of Wolverine Heavy Rare Earth Element Project in Labrador-REE Mineralized Potential Similar to Strange Lake and Tanbreez
